How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Progesterone API Market
- By Source: Synthetic Progesterone, Natural Progesterone (Extracted from Plant Sources)
- By Application: Hormone Replacement Therapy (HRT), Contraceptive Formulations, Fertility Treatments, Gynecological Disorders, Other Therapeutic Applications
- By Form: Micronized Progesterone, Non-Micronized Progesterone
- By End-Use Industry: Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Research and Development Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Synthetic Progesterone leads By Source at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 265 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.157 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.165 →
Full report · locked preview
Everything inside the Progesterone API Market report
A complete, evidence-based study - 11 chapters and 111 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Source 2
Application 5
Form 2
End-Use Industry 3
Companies profiled
BASF SE
Solvay SA
Croda International Plc
Bayer AG
Mitsubishi Chemical Corporation
Daiichi Sankyo Company
Limited
Hubei Biocause Pharmaceutical Co. Ltd.
Jiangsu Hengrui Medicine Co. Ltd.
Zhejiang NHU Co. Ltd.
Wuhan Yuancheng Gongchuang Technology Co. Ltd.
Hubei Yichang Pharmaceutical Co. Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Solvay SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Croda International Plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mitsubishi Chemical Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Daiichi Sankyo Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Hubei Biocause Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Zhejiang NHU Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Wuhan Yuancheng Gongchuang Technology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hubei Yichang Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Jiangsu Yabang Dyestuff Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shandong Xinhua Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Luye Pharma Group Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,990M by 2033 · 11.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Synthetic Progesterone78.6
- Natural Progesterone (Extracted from Plant Sources)21.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,364M → $3,046M · 10.6%
Europe$950.8M → $2,274M · 11.5%
Asia Pacific$868.2M → $2,145M · 12.0%
Latin America$537.4M → $1,386M · 12.6%
Middle East and Africa$413.4M → $957.8M · 11.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.612026
11.622027
11.632028
11.642029
11.662030
11.672031
11.692032
11.702033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BASF SE23.3
- Solvay SA13.0
- Croda International Plc8.8
- Bayer AG9.9
- Mitsubishi Chemical Corporation7.2
- Daiichi Sankyo Company9.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Source21.9%
Application18.9%
Form27.3%
End-Use Industry31.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.1
- Europe23.2
- Asia Pacific21.9
- Latin America14.1
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BASF SE | 89 | 81 | 96 | 79 | 97 | 89 | 89 |
| Solvay SA | 74 | 88 | 73 | 92 | 85 | 74 | 81 |
| Croda International Plc | 87 | 73 | 65 | 83 | 69 | 84 | 77 |
| Bayer AG | 72 | 69 | 78 | 70 | 62 | 77 | 71 |
| Mitsubishi Chemical Corporation | 64 | 73 | 66 | 56 | 74 | 52 | 64 |
| Daiichi Sankyo Company | 46 | 64 | 60 | 69 | 57 | 49 | 58 |
| Limited | 60 | 52 | 60 | 62 | 54 | 60 | 58 |
| Hubei Biocause Pharmaceutical Co. Ltd. | 46 | 37 | 55 | 47 | 52 | 45 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BASF SE
- Solvay SA
- Croda International Plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BASF SE | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Solvay SA | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Croda International Plc | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Bayer AG | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Mitsubishi Chemical Corporation | ◐ | ✓ | ◐ | − | ✓ | − |
| Daiichi Sankyo Company | − | − | ◐ | − | ◐ | − |
| Limited | ◐ | − | ◐ | − | − | ◐ |
| Hubei Biocause Pharmaceutical Co. Ltd. | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BASF SE89
2Solvay SA81
3Croda International Plc77
4Bayer AG71
5Mitsubishi Chemical Corporation64
6Daiichi Sankyo Company58
7Limited58
8Hubei Biocause Pharmaceutical Co. Ltd.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BASF SESolvay SA
Challenger2
Strong scale, closing on the leaders.
Croda International PlcBayer AG
Contender3
Focused players with pockets of strength.
Mitsubishi Chemical CorporationDaiichi Sankyo CompanyLimited
Niche1
Specialists in a single segment or region.
Hubei Biocause Pharmaceutical Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Source in North America, then scale across Progesterone API Market — a $360M beachhead inside a $6.11B market.
Beachhead (SOM)$360Mobtainable near-term
Serviceable (SAM)$2.50Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Synthetic Progesterone
Best fit — highest urgency & budget in Source.
Economic buyer77 fit
Natural Progesterone (Extracted from Plant Sources)
Strong fit — clear ROI and a fast path to value.
End user70 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Source in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Form
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Source leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Progesterone API Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation13%
Closed-won6%
$12.0KCAC
$48KLTV
4.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Progesterone API Market is a durable-growth opportunity — $8.96B by 2033, compounding at 8.2%.
TAM · 2025$4.77Btoday
TAM · 2033$8.96Bforecast
CAGR8.2%2027–2033
Cumulative$60.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.96BTotal addressable market
SAM$3.14BServiceable available market
SOM$655MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.2% CAGR
Demand compounds through 2033, outpacing GDP across Source.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Source moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.96BLarge & growingTAM by 2033 at 8.2% CAGR
$3.14BServiceable nowreachable with today’s model
$655MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.99BBear5.3% CAGR
$8.96BBase8.2% CAGR
$11.5BBull10.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Progesterone API Market — a $2.07B market by 2033. Plan: grow share from 8.8% to 16.2%.
Market size · 2033$2.07Btotal addressable
Market CAGR4.8%2027–2033
Target share16.2%from 8.8% today
Revenue ambition$336Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 16.2% | On track |
| Revenue | $185M | $336M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 36.7% | 38.6% | Behind |
| Customer retention | 86.9% | 96.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Source
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Source share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $38M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Source leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Progesterone API Market conversation — a $8.88B market you can size, segment and defend in minutes.
Market size · 2033$8.88Btotal opportunity
Growth6.9%CAGR to 2033
Addressable buyers1,429+accounts in scope
Typical ROI4.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Source
Goal Grow share in Source
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.3×return on cost, year one
< 3 mopayback period
$40K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BASF SESolvay SACroda International PlcBayer AGMitsubishi Chemical CorporationDaiichi Sankyo CompanyLimitedHubei Biocause Pharmaceutical Co. Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Progesterone API Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Progesterone API Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Profiling Beds Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportProfessional Wearable Devices in Healthcare Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportProfessional Water Flosser Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportProfessional Surgical Clipper Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportProfessional Supervision Service Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportProfessional Otoscopes Market
Market size, share, segmentation and regional forecast.
$800M market · 2025 base year
View reportProfessional Medical Scale Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportProfessional Laser Hair Removal Devices Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportProfessional Grade Wearable Medical Devices Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportProfessional ENT Chairs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportProfessional Dentist Chair Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportProfessional Defibrillator Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.